ID: ALA2335047

Max Phase: Preclinical

Molecular Formula: C22H47O5PS

Molecular Weight: 454.65

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCCCCCCCCCCCOC[C@@H](COP(O)(O)=S)OC

Standard InChI:  InChI=1S/C22H47O5PS/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26-20-22(25-2)21-27-28(23,24)29/h22H,3-21H2,1-2H3,(H2,23,24,29)/t22-/m0/s1

Standard InChI Key:  JYAROLONGLXUOT-QFIPXVFZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 454.65

Molecular Weight (Monoisotopic): 454.2882

AlogP: 6.51

#Rotatable Bonds: 23

Polar Surface Area: 68.15

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 2.15

CX Basic pKa:

CX LogP: 7.76

CX LogD: 4.53

Aromatic Rings: 0

Heavy Atoms: 29

QED Weighted: 0.14

Np Likeness Score: 0.61

References

1. Jiang G, Inoue A, Aoki J, Prestwich GD..  (2013)  Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists.,  23  (6): [PMID:23395664] [10.1016/j.bmcl.2013.01.002]

Source

Source(1):

• Scientific Literature